CTI BioPharma: Up after drug candidate shows promise in GVHD prevention

CTI Biopharma

22/03/2021 15:32

** Shares of drug developer  CTIC.O  rise 4.4% to $3.34
    ** CTIC says medical journal Clinical Cancer Research
published results from an early-stage study testing co's
experimental drug,  pacritinib, with two immune-suppressing
drugs for the prevention of acute graft-versus-host disease
(GVHD)  urn:newsml:reuters.com:*:nPnV1twZa
    ** GVHD is a complication that can occur after a stem cell
or bone marrow transplant in which the newly transplanted donor
cells attack the transplant recipient's body
    ** Co says results demonstrated that pacritinib, combined
with the other drugs, has a promising safety profile and
exhibits preliminary therapeutic activity in preventing acute
GVHD after transplant
    ** Pacritinib is also being developed by co to treat
myelofibrosis, a type of bone marrow cancer 
    ** Stock had fallen 0.6% YTD as of its last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))